Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells

Yang,Chuang; Liu,Hai-Zhong; Fu,Zhong-Xue

doi:10.3892/or.2012.1868

Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells

Authors:
- Chuang Yang
- Hai-Zhong Liu
- Zhong-Xue Fu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Third Hospital of Mianyang, Mianyang, Sichuan 621000, P.R. China, Department of Gynecology and Obstetrics, The Second Hospital of Chengdu, Chengdu 400016, P.R. China, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: June 15, 2012 https://doi.org/10.3892/or.2012.1868
Pages: 1006-1012

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin is one of the agents used against colorectal cancer. Using PEG-liposome encapsulated oxaliplatin may enhance the accumulation of drugs in tumor cells, inducing apoptosis. However, the mechanism of action of PEG-liposome encapsulated oxaliplatin remains unclear. SW480 human colorectal cancer cells were treated with empty PEG-liposomes, free oxaliplatin or PEG-liposomal oxaliplatin. Cell cycle and apoptosis were assessed using fluorescence confocal microscopy and terminal deoxynucleotidyl transferase-mediated dUTP-fluorescein nick-end-labeling (TUNEL). Western blotting was used to analyze the expression of pro-apoptotic, anti-apoptotic and cyclin proteins. We found that PEG-liposomal oxaliplatin induced a stronger apoptotic response than empty PEG-liposomes or free oxaliplatin. Moreover, expression of Cyclin D1 increased, whereas expression of Cyclin A decreased after treatment with PEG-liposomal oxaliplatin. Furthermore, the cell cycle was arrested in the G1 phase. The results presented here indicate that PEG-liposome entrapment of oxaliplatin enhances the anticancer potency of the chemotherapeutic agent. The effect of PEG-liposomal oxaliplatin on apoptosis of SW480 human colorectal cancer cells may be through regulation of expression of Cyclin A or Cyclin D1, as well as pro-apoptotic and anti-apoptotic proteins.

View Figures

View References

1	Pasetto LM, D’Andrea MR, Rossi E and Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 59:159–168. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lammers T, Hennink WE and Storm G: Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 99:392–397. 2008. View Article : Google Scholar : PubMed/NCBI
3	Michor FJ, Iwasa Y, Lengauer C and Nowak MA: Dynamics of colorectal cancer. Semin Cancer Biol. 15:484–493. 2005. View Article : Google Scholar
4	Hong M, Zhu S, Jiang Y, Tang G and Pei Y: Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release. 133:96–102. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hussain S, Plückthun A, Allen TM and Zangemeister-Wittke U: Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther. 6:3019–3027. 2007. View Article : Google Scholar : PubMed/NCBI
6	Pietrangeli A, Leandri M, Terzoli E, Jandolo B and Garufi C: Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol. 56:13–16. 2006. View Article : Google Scholar : PubMed/NCBI
7	Stern ST, Hall JB, Yu LL, Wood LJ, Paciotti GF, Tamarkin L, Long SE and McNeil SE: Translational considerations for cancer nanomedicine. J Control Release. 146:164–174. 2010. View Article : Google Scholar : PubMed/NCBI
8	Sun W, Zou W, Huang G, Li A and Zhang N: Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J Drug Target. 16:357–365. 2008. View Article : Google Scholar : PubMed/NCBI
9	Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1066:29–36. 1991. View Article : Google Scholar : PubMed/NCBI
10	Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP and Huang L: Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta. 1062:142–148. 1991. View Article : Google Scholar : PubMed/NCBI
11	Tsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI
12	Hao Z and Mak TW: Type I and type II pathways of fas-mediated apoptosis are differentially controlled by XIAP. J Mol Cell Biol. 2:63–64. 2010. View Article : Google Scholar : PubMed/NCBI
13	Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
14	Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
15	Jaattela M and Tschopp J: Caspase-independent cell death in T lymphocytes. Nat Immunol. 4:416–423. 2003. View Article : Google Scholar : PubMed/NCBI
16	Walters J, Pop C, Scott FL, Drag M, Swartz P, Mattos C, Salvesen GS and Clark AC: A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J. 424:335–345. 2009. View Article : Google Scholar : PubMed/NCBI
17	Bortner DM and Rosenberg MP: Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. Cell Growth Differ. 6:1579–1589. 1995.PubMed/NCBI
18	Owa T, Yoshino H, Yoshimatsu K and Nagasu T: Cell cycle regulation in the Gl phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem. 8:1487–1503. 2001. View Article : Google Scholar : PubMed/NCBI
19	Buolamwini JK: Cell cycle molecular targets in hovel anticancer drug discovery. Curr Pharm Des. 6:379–392. 2000. View Article : Google Scholar : PubMed/NCBI
20	McDonald ER and El-Deiry WS: Cell cycle control as a basis for cancer drug development. Int J Oncol. 16:871–886. 2000.PubMed/NCBI
21	Yang C, Liu HZ, Fu ZX and Lu WD: Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. BMC Biotechnol. 11:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yang C, Liu HZ, Lu WD and Fu ZX: PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma. Oncol Rep. 25:1621–1628. 2011.PubMed/NCBI
23	Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, et al: XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 460:1035–1039. 2009. View Article : Google Scholar : PubMed/NCBI
24	Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the cysteine residues in IκBα kinase and NF-κB(p65) by xanthohumol leads to suppression of NF-κB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood. 113:2003–2013. 2009.
25	Nobili S, Checcacci D, Filippelli F, Del Buono S, Mazzocchi V, Mazzei T and Mini E: Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. J Chemother. 20:622–631. 2008. View Article : Google Scholar
26	Abizon D and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA. 85:6949–6953. 1988. View Article : Google Scholar : PubMed/NCBI
27	Gabizon AA: Stealth liposomes and tumor targeting: a step further in the quest for the magic bullet. Clin Cancer Res. 7:223–225. 2001.PubMed/NCBI
28	Zalipsky S, Brandeis E, Newman MS and Woodle MC: Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 53:71–74. 1994. View Article : Google Scholar : PubMed/NCBI
29	Panwar P, Pandey B, Lakhera PC and Singh KP: Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed. 5:101–108. 2010.PubMed/NCBI
30	Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S and Gabizon A: Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 6:1949–1957. 2000.PubMed/NCBI
31	Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C and Wei Y: BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One. 6:e205862011. View Article : Google Scholar : PubMed/NCBI
32	Pramanik KC, Boreddy SR and Srivastava SK: Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS One. 6:e201512011. View Article : Google Scholar
33	Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
34	Santamaria D and Ortega S: Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci. 11:1164–1188. 2006. View Article : Google Scholar : PubMed/NCBI
35	Viallard JF, Lacombe F, Belloc F, Pellegrin JL and Reiffers J: Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother. 5:109–129. 2001. View Article : Google Scholar : PubMed/NCBI
36	Hsia DA, Tepper CG, Pochampalli MR, Hsia EY, Izumiya C, Huerta SB, Wright ME, Chen HW, Kung HJ and Izumiya Y: KDM8, a H3K36me2 histone demethylase that acts in the Cyclin A1 coding region to regulate cancer cell proliferation. Proc Natl Acad Sci USA. 107:9671–9676. 2010. View Article : Google Scholar : PubMed/NCBI
37	Sun PC, Tzao C, Chen BH, Liu CW, Yu CP and Jin JS: Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci. 17:762010. View Article : Google Scholar : PubMed/NCBI
38	Tung JN, Chiang CC, Tsai YY, Chou YY, Yeh KT, Lee H and Cheng YW: CyclinD1 protein expressed in pterygia is associated with β-catenin protein localization. Mol Vis. 16:2733–2738. 2010.PubMed/NCBI
39	Prall OW, Sarcevic B, Musgrove EA, Watts CK and Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased Cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem. 272:10882–10894. 1997. View Article : Google Scholar
40	Zhu X, Ohtsubo M, Böhmer RM, Roberts JM and Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of Cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol. 33:391–403. 1996. View Article : Google Scholar : PubMed/NCBI